{
    "abstract": "Whether adjuvant chemotherapy should be different for patients with stage II and III gastric cancer is unknown.\nWe retrospectively analyzed the effects of adjuvant chemotherapy on the outcomes of 140 and 256 patients with stage II and III gastric cancer, respectively, between January 2008 and December 2018. Chemotherapies were stratified as fluoropyrimidine plus platinum versus fluoropyrimidine alone, tegafur/gimeracil/octeracil (S-1)-containing versus non-S-1-containing regimens, and S-1 plus cisplatin versus S-1 alone.\nThe median age of patients was 67.0 (range 24.6-98.8) years. With a median follow-up of 105 months, recurrence occurred in 32 (22.9%) and 130 (50.8%) patients with stage II and III disease, respectively. Adjuvant chemotherapy was administered as fluoropyrimidine monotherapy to 68 (48.6%) and 73 (28.5%) patients, fluoropyrimidine plus platinum to 9 (6.4%) and 104 (40.6%) patients, and none to 63 (45.0%) and 79 (30.9%) patients with stage II and III gastric cancer, respectively. Doublet chemotherapy was associated with longer disease-free survival (DFS) (26.5 vs. 15.2 months, P\u00a0=\u00a00.001) and overall survival (OS) (41.2 vs. 22.0 months, P\u00a0<\u00a00.001) than fluoropyrimidine monotherapy for stage IIIB-IIIC disease. Furthermore, S-1-containing regimens prolonged DFS (57.4 vs. 21.9 months, P\u00a0=\u00a00.044) and OS (81.4 vs. 28.6 months, P\u00a0=\u00a00.023) compared with non-S-1-containing chemotherapy in stage III disease.\nAlthough fluoropyrimidine monotherapy is feasible for stage II-IIIA disease, doublet chemotherapy is significantly associated with longer survival than monotherapy for stage IIIB-IIIC disease. S-1-containing regimens might lead to longer survival than non-S-1-containing chemotherapy in stage III gastric cancer.",
    "authors": [
        {
            "affiliation": "Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.",
            "firstname": "Hsiu-Tzu",
            "initials": "HT",
            "lastname": "Wang"
        },
        {
            "affiliation": "Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; College of Medicine, School of Medicine, China Medical University, Taichung, Taiwan; Cancer Center, China Medical University Hospital, Taichung, Taiwan.",
            "firstname": "Chang-Fang",
            "initials": "CF",
            "lastname": "Chiu"
        },
        {
            "affiliation": "College of Medicine, School of Medicine, China Medical University, Taichung, Taiwan; Department of Surgery, China Medical University Hospital, Taichung, Taiwan.",
            "firstname": "Horng-Ren",
            "initials": "HR",
            "lastname": "Yang"
        },
        {
            "affiliation": "Department of Surgery, China Medical University Hospital, Taichung, Taiwan.",
            "firstname": "Long-Bin",
            "initials": "LB",
            "lastname": "Jeng"
        },
        {
            "affiliation": "Bachelor of Science in Kinesiology, Exercise Science, The University of Texas at Austin, TX, 78712, USA.",
            "firstname": "En-Jia",
            "initials": "EJ",
            "lastname": "Bai"
        },
        {
            "affiliation": "College of Medicine, School of Medicine, China Medical University, Taichung, Taiwan; Department of Surgery, China Medical University Hospital, Taichung, Taiwan.",
            "firstname": "Te-Hong",
            "initials": "TH",
            "lastname": "Chen"
        },
        {
            "affiliation": "College of Medicine, School of Medicine, China Medical University, Taichung, Taiwan; Department of Surgery, China Medical University Hospital, Taichung, Taiwan.",
            "firstname": "Chun-Chieh",
            "initials": "CC",
            "lastname": "Yeh"
        },
        {
            "affiliation": "Cancer Center, China Medical University Hospital, Taichung, Taiwan.",
            "firstname": "Chien-Lun",
            "initials": "CL",
            "lastname": "Chu"
        },
        {
            "affiliation": "Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; College of Medicine, School of Medicine, China Medical University, Taichung, Taiwan. Electronic address: 013664@tool.caaumed.org.tw.",
            "firstname": "Li-Yuan",
            "initials": "LY",
            "lastname": "Bai"
        }
    ],
    "conclusions": "Although fluoropyrimidine monotherapy is feasible for stage II-IIIA disease, doublet chemotherapy is significantly associated with longer survival than monotherapy for stage IIIB-IIIC disease. S-1-containing regimens might lead to longer survival than non-S-1-containing chemotherapy in stage III gastric cancer.",
    "copyrights": "Copyright \u00a9 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.",
    "doi": "10.1016/j.jfma.2024.04.020",
    "journal": "Journal of the Formosan Medical Association = Taiwan yi zhi",
    "keywords": [
        "Adjuvant chemotherapy",
        "Combination therapy",
        "Gastric cancer",
        "Overall survival",
        "Propensity score analysis",
        "Relapse-free survival"
    ],
    "methods": null,
    "publication_date": "2024-05-09",
    "pubmed_id": "38719675",
    "results": "The median age of patients was 67.0 (range 24.6-98.8) years. With a median follow-up of 105 months, recurrence occurred in 32 (22.9%) and 130 (50.8%) patients with stage II and III disease, respectively. Adjuvant chemotherapy was administered as fluoropyrimidine monotherapy to 68 (48.6%) and 73 (28.5%) patients, fluoropyrimidine plus platinum to 9 (6.4%) and 104 (40.6%) patients, and none to 63 (45.0%) and 79 (30.9%) patients with stage II and III gastric cancer, respectively. Doublet chemotherapy was associated with longer disease-free survival (DFS) (26.5 vs. 15.2 months, P\u00a0=\u00a00.001) and overall survival (OS) (41.2 vs. 22.0 months, P\u00a0<\u00a00.001) than fluoropyrimidine monotherapy for stage IIIB-IIIC disease. Furthermore, S-1-containing regimens prolonged DFS (57.4 vs. 21.9 months, P\u00a0=\u00a00.044) and OS (81.4 vs. 28.6 months, P\u00a0=\u00a00.023) compared with non-S-1-containing chemotherapy in stage III disease.",
    "title": "Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-up.",
    "xml": "<Element 'PubmedArticle' at 0x788503fd93a0>"
}